| Title: |
Improved post-transplant outcomes since 2000 for Ph-positive acute lymphoblastic leukemia in first remission: A study from the EBMT Acute Leukemia Working Party. |
| Authors: |
Bazarbachi, A.; Labopin, M.; Dalle, I. A.; Yakoub-Agha, Ibrahim; Socié, G.; Schroeder, T.; Blaise, D.; Poiré, X.; Balsat, M.; Salmenniemi, U.; Kröger, N.; Kulagin, A.; Wagner-Drouet, E. M.; Wu, D.; Brissot, E.; Nagler, A.; Giebel, S.; Ciceri, F.; Mohty, M. |
| Contributors: |
American University of Beirut (AUB); CHU Saint-Antoine AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU); Institute for Translational Research in Inflammation - U 1286 (INFINITE); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille); Hopital Saint-Louis AP-HP (AP-HP); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); University Hospital Essen (AöR); Cliniques universitaires St Luc Bruxelles; Service d’Hématologie Centre Hospitalier Lyon Sud - HCL; Centre Hospitalier Lyon Sud CHU - HCL (CHLS); Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL); Helsinki University Hospital Finland (HUS); University Hospital Hamburg-Eppendorf; Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf Hamburg (UKE); Pavlov First Saint Petersburg State Medical University St. Petersburg; University Medical Center Mainz; Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University (JGU); Suzhou Vocational University; Chaim Sheba Medical Center; Institute of Physics Gliwice; Silesian University of Technology; Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University Milan, Italie (UniSR) |
| Source: |
ISSN: 2572-9241 ; HemaSphere ; https://lilloa.hal.science/hal-05329444 ; HemaSphere, 2025, HEMASPHERE, 9 (4), pp.e70117. ⟨10.1002/hem3.70117⟩. |
| Publisher Information: |
CCSD; Lippincott, Williams & Wilkins |
| Publication Year: |
2025 |
| Collection: |
LillOA (HAL Lille Open Archive, Université de Lille) |
| Subject Terms: |
[SDV]Life Sciences [q-bio] |
| Description: |
International audience ; Allogeneic hematopoietic cell transplantation (allo-HCT) remains a curative treatment for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in their first complete remission (CR1). Recent results using the combination of blinatumomab and second- or third-generation tyrosine kinase inhibitors have challenged the necessity of allo-HCT in CR1. Here we assessed real-world changes over time in transplant characteristics and outcomes in adult patients with Ph+ ALL in CR1, using a large dataset from the European Society for Blood and Marrow Transplantation registry. A total of 3292 patients (45% female; median age 45 years) who underwent allo-HCT from 2001 to 2020 were included. Over four periods (2001–2005, 2006–2010, 2011–2015, and 2016–2020), the 3-year cumulative incidence of relapse decreased from 41% to 19%, and non-relapse mortality decreased from 25% to 17% (p < 0.001 for both). Correspondingly, 3-year leukemia-free survival (LFS) improved from 34% to 64%, and overall survival (OS) from 47% to 75% (p < 0.001 for both). Graft versus host disease-free and relapse-free survival also improved from 26% to 49% (p < 0.001). Factors negatively affecting LFS included older age, male gender, male donor and measurable residual disease (MRD) positivity pre-transplant, while total body conditioning (TBI) positively affected LFS. OS was positively influenced by younger age, female gender, matched sibling donor, TBI, and T cell depletion. Importantly, improvement in post-transplant outcomes over time was observed regardless of pre-transplant MRD status. In conclusion, we observed an impressive improvement over time in post-transplant outcomes of Ph+ ALL. These large-scale data can serve as a benchmark for future studies. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/40224161; PUBMED: 40224161 |
| DOI: |
10.1002/hem3.70117 |
| Availability: |
https://lilloa.hal.science/hal-05329444; https://lilloa.hal.science/hal-05329444v1/document; https://lilloa.hal.science/hal-05329444v1/file/HemaSphere%20-%202025%20-%20Bazarbachi%20-%20Improved%20post%E2%80%90transplant%20outcomes%20since%202000%20for%20Ph%E2%80%90positive%20acute%20lymphoblastic%20leukemia.pdf; https://doi.org/10.1002/hem3.70117 |
| Rights: |
https://creativecommons.org/licenses/by-nc-nd/4.0/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.765D78BE |
| Database: |
BASE |